3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Hepatocellular
2
Interventions
Bevacizumab
47
lenvatinib
36
atezolizumab
36
durvalumab
28
tremelimumab
23
sintilimab
19
Nivolumab
18
pembrolizumab
14
Radiosurgery
13
tislelizumab
11
Specimen Handling
10
Ipilimumab
10
camrelizumab
8
apatinib
8
Oxaliplatin
8
Immune Checkpoint Inhibitors
8
Fluorouracil
8
Cyclophosphamide
8
Blood Specimen Collection
8
regorafenib
7
cabozantinib
7
fludarabine
6
Sorafenib
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Leucovorin
6
donafenib
5
Surgical Procedures, Operative
5
Injections
5
Immunoglobulin G
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Hepatocellular
×
icaritin
×
Clear all
NCT06893887
2025-07-02
ICT-HCC
Nanjing Tianyinshan Hospital
Phase NA
Recruiting
300 enrolled
NCT05594927
2024-08-07
BESTPOP
Beijing Shenogen Biomedical Co., Ltd
Phase 3
Recruiting
261 enrolled